Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT02238184
Last Updated: 2014-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
105 participants
OBSERVATIONAL
2001-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
NCT02238171
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
NCT02233894
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02233881
Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
NCT02238145
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
NCT02238197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Obstructive Pulmonary Disease
patients receiving Atrovent®
Atrovent®
Cronic Obstructive Pulmonary Disease
patients receiving Ventilat®
Ventilat®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atrovent®
Ventilat®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Only patients who showed following diagnosis parameters were to be considered for inclusion
* FEV1 (Forced expiratory volume in 1 second) and FEV1/VC (vital capacity) \<70%
* Reversibility FEV1 \<12% in the last 6 months
* Smoker or Ex-smoker (\>10 Pack years)
* Asthma to be excluded
Exclusion Criteria
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
244.2499
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.